Novo Nordisk and Hims Forge Deal to Sell Wegovy and Ozempic, Legal Battle Ends

Negotiations that started with a lawsuit have now turned into a collaboration: Novo Nordisk is teaming up with telehealth firm Hims & Hers to sell its weight-loss drugs Wegovy and Ozempic through Hims' platform across the U.S. This development puts an end to a recent legal spat over cheaper compounded versions of the medications.

Just last month, Novo Nordisk took legal action against Hims over a $49 compounded variant of Wegovy, aiming to safeguard its original formula against knockoffs flooding the market. But with this new agreement, customers on Hims' platform can purchase FDA-approved Wegovy and Ozempic injectables-and notably, the Wegovy pill-at Novo's own self-pay prices.

Mike Doustdar, CEO of Novo Nordisk, revealed that Wegovy's pill form had already amassed over 600,000 prescriptions since its launch a couple of months ago. Telehealth partnerships, he indicated, are pivotal to speeding up distribution, especially against robust competition from Eli Lilly in the weight-loss drug space.

Price cuts seem to be a strategic play in this battle; Novo has slashed the monthly cost of its GLP-1 drugs from around $1,000 to a range between $149 and $299 on its websites. Doustdar highlighted that the new pricing puts authentic Wegovy and Ozempic products nearly on par with compounded alternatives, removing a key incentive for consumers to seek cheaper but unapproved versions.

The deal follows the FDA's recent warning to approximately 30 telehealth companies about deceptive marketing of compounded GLP-1 drugs, cautioning that these products aren't equivalent to FDA-approved medications. This likely nudged Hims to shift away from promoting compounded GLP-1s to doubling down on branded, approved treatments.

Andrew Dudum, Hims' CEO, remarked that they've pivoted their U.S. weight-loss business towards these FDA-endorsed drugs in response to growing consumer demand for more affordable, legitimate options. Although Hims will cease advertising compounded GLP-1 drugs, it will still offer them when medically necessary.

Interestingly, Novo Nordisk is pausing the lawsuit but hasn't ruled out restarting it down the line, signaling some lingering caution. This isn't their first rodeo with Hims on this front; they ended a previous agreement last year over issues around compounded drug marketing.

So, with this partnership, both companies seem to be hedging their bets-stabilizing the market around bona fide products while keeping an eye on the murky terrain of compounded drug alternatives.